About the Clinical Trial
This is a Phase 2b randomized, double-blind placebo-controlled study to investigate the mechanism(s) of action of tirzepatide in the kidney in participants who are overweight or living with obesity and coexisting chronic kidney disease, with and without type 2 diabetes. Tirzepatide has been shown effective in lowering blood glucose and inducing weight loss.
Participants will be randomized to receive once weekly subcutaneous injection of tirzepatide or placebo for 52 weeks, there are 12 hospital visits to receive assessments and education, including kidney Magnetic Resonance Imaging scan, Electrocardiogram, blood and urine tests and other methods, since these are informative about overall kidney health.
Travel reimbursement is available.
Eligibility Requirements
Older than 18 years of age, willing to sign Informed Consent
Body Mass index ≥ 27 kg/m2
Decreased kidney function: estimated Glomerular filtration rate ≥ 30 to ≤ 60 ml/min/1.73 m2, estimated Glomerular filtration rate ≥ 30 to ≤ 75 ml/min/1.73 m2 if Urinary albumin creatinine ratio > 30 mg/g
If a patient with type 2 diabetes, Glycated hemoglobin ≥ 7.0% to ≤10.5%
On a stable dose of high blood pressure drug Angiotensin-converting enzyme inhibitor or Angiotensin receptor blocker, or sodium-glucose cotransporter-2 inhibitor, or diuretic for at least 30 days prior screening.